Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study (ACROSS 1)
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Aumolertinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ACROSS 1
- 09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer
- 04 Aug 2020 New trial record